Insider Trading March 31, 2026

C3.ai Director Executes Offset Transactions as Analysts Trim Targets After Weak Quarter

Director Snabe Jim H. sells and repurchases equal blocks of Class A stock as the company grapples with a sizeable revenue miss and lowered analyst outlooks

By Derek Hwang AI
C3.ai Director Executes Offset Transactions as Analysts Trim Targets After Weak Quarter
AI

C3.ai director Snabe Jim H. sold 10,000 Class A shares for $8.08 apiece and, on the same day, bought 10,000 Class A shares at $7.73, leaving him with a stated direct holding of 385,000 shares and an indirect stake of 28,000 through BJHS Invest ApS. The transactions come amid a difficult quarter for the enterprise AI company - fiscal Q3 results materially missed expectations, several brokers cut price targets and the company issued disappointing fourth-quarter revenue guidance and announced workforce reductions.

Key Points

  • Director Snabe executed both a sale (10,000 shares at $8.08) and a purchase (10,000 shares at $7.73) of C3.ai Class A stock on March 27, 2026; direct ownership now 385,000 shares and indirect ownership 28,000 shares via BJHS Invest ApS.
  • Analysts reduced price targets after a material Q3 revenue miss - DA Davidson to $7 (Underperform), Wolfe Research to $6, Canaccord to $7 (Hold), and KeyBanc to $6 (Underweight).
  • C3.ai’s Q4 revenue outlook of $48M-$52M is well below the $77.47M analyst estimate and coincided with a 22.7% drop in the share price; the company also announced workforce reductions.

Director Snabe Jim H. disclosed two offsetting trades in C3.ai, Inc. (NYSE: AI) executed on March 27, 2026. He sold 10,000 shares of Class A Common Stock at a price of $8.08 per share, generating proceeds of $80,800. On the same trading day, Snabe purchased 10,000 Class A shares at $7.73 each, for a cash outlay of $77,300.

Following those transactions, the director is reported to directly hold 385,000 shares of the company’s Class A stock and to indirectly hold 28,000 shares through BJHS Invest ApS. The transaction filings do not provide further commentary on the rationale behind the buys and sells.

Market observers have noted contrasting perspectives on the stock. An InvestingPro analysis referenced alongside the disclosure indicates that C3.ai appears undervalued at current levels. The platform’s Pro Research Report is cited as offering more in-depth coverage for C3.ai and for more than 1,400 U.S. equities.

These insider transactions coincide with a period of investor concern for C3.ai following its fiscal third-quarter 2026 performance. The company’s results for that quarter fell materially short of consensus expectations, prompting multiple brokerages to re-evaluate their outlooks.

DA Davidson reduced its price objective to $7 and kept an Underperform rating on the shares. Wolfe Research identified a roughly 30% shortfall versus revenue targets, attributing the miss to weak sales execution and a shortfall in non-recurring subscription revenue; Wolfe adjusted its price target to $6. Canaccord highlighted revenue decline concerns despite reporting a 134% year-over-year increase in federal, defense and aerospace bookings, and cut its price target to $7 while maintaining a Hold rating. KeyBanc pointed to execution shortcomings and a significant third-quarter revenue miss, lowering its price target to $6 and maintaining an Underweight rating.

In its forward guidance, C3.ai forecasted fourth-quarter revenue in a range between $48 million and $52 million. That outlook sits well below the analyst consensus figure of $77.47 million and was a key factor in a 22.7% decline in the company’s share price. The firm additionally announced workforce reductions around the time of the guidance announcement, a move that further affected market sentiment.

The reported insider buying and selling, the mixed analyst commentary and the company’s lowered revenue outlook together present a concise snapshot of the current tensions around C3.ai’s execution and valuation. Investors seeking deeper, model-driven research on the company are referred to the Pro Research Report referenced by InvestingPro.


Key points

  • Director Snabe Jim H. sold 10,000 Class A shares at $8.08 and bought 10,000 Class A shares at $7.73 on March 27, 2026, resulting in direct ownership of 385,000 shares and indirect ownership of 28,000 shares through BJHS Invest ApS.
  • Multiple brokerages trimmed price targets after C3.ai’s fiscal Q3 miss - DA Davidson to $7 (Underperform), Wolfe Research to $6, Canaccord to $7 (Hold), and KeyBanc to $6 (Underweight).
  • C3.ai projected Q4 revenue of $48M-$52M versus an analyst estimate of $77.47M; the guidance and announced workforce cuts contributed to a 22.7% share-price decline.

Risks and uncertainties

  • Revenue execution risk - the company reported a substantial Q3 revenue miss and provided Q4 guidance well below analyst estimates, indicating continued top-line uncertainty.
  • Operational and execution risk - multiple brokers cited execution shortcomings, and announced workforce reductions may introduce additional near-term operational disruption.
  • Market sentiment risk - lowered analyst price targets and the sharp decline in share price reflect investor concern, which may increase volatility in the company’s stock and affect broader enterprise software market sentiment.

Risks

  • Revenue shortfall risk - the company’s Q3 results and Q4 guidance indicate persistent revenue uncertainty, affecting enterprise software demand and investor confidence.
  • Execution risk - cited by several brokers after the substantial revenue miss, raising concerns about sales effectiveness and delivery.
  • Operational disruption risk - announced workforce cuts may have short-term impacts on operations and product development within the technology and software sectors.

More from Insider Trading

ArrowMark Financial Director Buys 1,500 Shares as Company Launches Rights Offering Mar 31, 2026 Strawberry Fields REIT Director Acquires $17,465 Stake; Company Announces Dividend and Executive Pay Changes Mar 31, 2026 Edgewise Therapeutics CMO Disposes Shares While Exercising Options Amid Positive Trial News Mar 31, 2026 Platinum Equity Disposes of 1.35M Ingram Micro Shares in $28.8M Trade Mar 31, 2026 Adaptive Biotechnologies President Disposes of $751k in Stock While Exercising Options Mar 31, 2026